Saroglitazar Currently Has No Established Role in Lean NASH
Saroglitazar is not recommended for lean NASH as it lacks evidence from high-quality trials in this specific population and is not mentioned in current guidelines for lean NAFLD/NASH management. The most recent and authoritative guideline on lean NASH from the AGA (2022) specifically recommends pioglitazone 30 mg daily or vitamin E (800 IU daily, in non-diabetics) as the only pharmacological options for biopsy-confirmed lean NASH without cirrhosis 1.
Why Saroglitazar Is Not Recommended
Absence from Guidelines
The 2022 AGA Clinical Practice Update on lean NAFLD—the most comprehensive and recent guideline addressing this specific population—makes no mention of saroglitazar 1. This guideline explicitly states that evidence on effective pharmacotherapy in lean patients with NASH remains inadequate, and only endorses vitamin E and pioglitazone as first-line options based on AASLD and EASL recommendations.
The 2024 EASL-EASD-EASO guidelines similarly do not include saroglitazar in their recommendations for MASLD/MASH treatment 2. These guidelines recommend resmetirom for non-cirrhotic MASH with significant fibrosis, but explicitly state that pioglitazone "cannot be recommended as a MASH-targeted therapy" despite being safe to use, due to lack of robust phase III trial data 2.
Limited Evidence Base
While saroglitazar has shown promise in general NAFLD populations 3, there is no specific evidence demonstrating efficacy in lean NASH patients. The drug development landscape for NASH predominantly focuses on overweight and obese patients, with many trials explicitly excluding lean individuals 1.
What IS Recommended for Lean NASH
First-Line Pharmacotherapy
For biopsy-confirmed lean NASH without cirrhosis:
Pioglitazone 30 mg daily: May be considered, though requires individualized assessment due to adverse effects including weight gain, peripheral edema, heart failure risk, and fractures 1
Vitamin E 800 IU daily: May be considered in patients without diabetes or cirrhosis, though concerns exist regarding potential increases in all-cause mortality, hemorrhagic stroke, and prostate cancer 1
Lifestyle Modifications Remain Essential
Even in lean patients, the following are recommended 1:
- Modest weight loss of 3-5% has proven beneficial
- Limit fructose and sugar-sweetened beverages (particularly important in younger lean patients)
- Increase physical activity and exercise to reduce visceral fat
- Decrease visceral adiposity despite normal BMI
Critical Caveats
The Lean NASH Paradox
Lean NASH patients face similar or elevated risks compared to obese NASH patients for:
- All-cause mortality (1.6-fold increase)
- Advanced fibrosis and cirrhosis
- Hepatocellular carcinoma
- Cardiovascular disease 4
This occurs despite lower prevalence of traditional metabolic comorbidities, making early identification and treatment crucial.
Pathophysiologic Differences
Lean NASH is characterized by distinct features 4:
- Visceral obesity despite normal BMI
- Sarcopenia
- Strong genetic determinants (PNPLA3, TM6SF2, MBOAT7 variants)
- Gut dysbiosis
- Altered bile acid metabolism
These differences underscore why extrapolating data from obese NASH populations to lean patients is problematic.
Emerging Therapies Not Yet Validated
The 2022 AGA guideline explicitly states that GLP-1 agonists and SGLT2 inhibitors are premature for lean NASH treatment until further data are available, though they may be used for comorbid conditions like diabetes 1.
Bottom Line
Use pioglitazone 30 mg daily or vitamin E 800 IU daily (if non-diabetic, non-cirrhotic) for biopsy-confirmed lean NASH. Saroglitazar has no established role in this population and should not be used as NASH-targeted therapy. Focus on lifestyle modifications including modest weight loss, fructose restriction, and increased physical activity as foundational therapy.